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Background: Nitrite in exhaled breath condensate (EBC) has been shown to be elevated in cystic
fibrosis (CF), while exhaled nitric oxide (FENO) is paradoxically low. This has been argued to
reflect increased metabolism of NO while its diffusion is obstructed by mucus. However, we
wanted to study the possible influence of salivary nitrite and bacterial nitrate reduction on these
parameters in CF patients by the intervention of an anti-bacterial mouthwash.
Methods: EBC and saliva were collected from 15 CF patients (10e43 years) and 15 controls (9e44
years) before and 5 min after a 30 s chlorhexidine mouthwash, in parallel with measurements of
FENO. Nitrite and nitrate concentrations were measured fluorometrically.
Results: EBC nitrite, but not nitrate, was significantly higher in the CF patients (median 3.6 vs
1.3 mM in controls, p< 0.05) and decreased after mouthwash in both groups (3.6e1.4 mM,
p < 0.01; 1.3e0.5 mM, p < 0.01). Salivary nitrite correlated significantly to EBC nitrite
(rZ 0.60, p< 0.001) and decreased correspondingly after chlorhexidine, whereas salivary
nitrate increased. FENO was lower in CF and the difference between patients and controls
was accentuated after mouthwash (5.4 vs 8.4 ppb in controls, p< 0.05).
Conclusion: EBC nitrite mainly originates in the pharyngo-oral tract and its increase in CF is
possibly explained by a regional change in bacterial activity. The limited lower airway contribu-
tion supports the viewof a genuinely impaired formation andmetabolism of NO in CF, rather than
poor diffusion of the molecule.
ª 2008 Elsevier Ltd. All rights reserved.Astrid Lindgren Children’s
l/Solna, S-171 76 Stockholm,
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The formation of nitric oxide (NO) is influenced by inflam-
matory activity in the airway mucosa and measurements of
exhaled NO (FENO; fraction of expired NO) can be used for.
188 W. Zetterquist et al.evaluating the activity of different inflammatory airway
conditions.1,2 These are, in general, associated with an
increase of FENO, which is believed to originate from an up-
regulation of the inducible nitric oxide synthase (iNOS) in the
airway epithelium, as shown in asthmatics.3e5 However,
repeated studies on patients with cystic fibrosis (CF) have
shown similar6,7 or even decreased8,9 levels of FENO as
compared to healthy controls. This has been considered
a paradox, since CF is characterised as a disorder with an
intense airway inflammation, in parallel with often chronic
colonisations of bacterial pathogens, and a progressive
impairment of lung function.10 Poor diffusion of NO through
the thick mucus of the CF airways, a reduced expression of
epithelial iNOS, and substrate deficiency (i.e. lack of L-
arginine) have been argued to explain this inconsistency, but
the issue is still unclear.11,12
Analyses of soluble NO metabolites in exhaled breath
condensate (EBC) have been suggested as a simple, yet non-
invasive, alternative method to recordings of FENO, which
could provide further information on the role of nitrogen
oxides in the pathology of airway inflammation.13 Nitrite and
nitrate, for example, can be formed through oxidation of NO
and their levels in EBC could possibly reflect iNOS activity. Of
these two, nitrite is the most extensively studied in EBC and
increased levels have been reported in paediatric and adult
asthma,14,15 as well as in CF.16,17 EBC nitrate is shown to be
elevated in asthmatics and smokers,18 whereas data are
deficient regarding CF. The combination of increased EBC
nitrite and low FENO in CF has been argued to reflect
a genuinely induced formation of NO, but with its diffusion
being impaired and therefore rather metabolised to
nitrite.11,16,17 However, there is also a possible source of
nitrite and nitrate through salivary secretion in the upper
airway region. A large part of the body’s circulating nitrate,
from endogenous metabolism or dietary sources, is excreted
with the saliva and reduced to nitrite in the pharyngo-oral
tract by local bacteria.19 This salivary nitrite generates NO
through further non-enzymatic reduction20 and can thereby
influence measurements of FENO.21,22 More recently it has
also been demonstrated that salivary nitrite contributes to
EBC nitrite.23 Since the formation of salivary nitrite might be
affected in CF patients, given their potentially different
bacterial environment in upper and lower airways, this
contribution could be further influenced.
Therefore, we wanted to analyse nitrite and nitrate in
EBC and saliva, in parallel with measurements of FENO,
before and after the application of an anti-bacterial
mouthwash in children and adults with CF and compare the
results to values from age-matched healthy controls.
Methods
Subjects
The 15 patients with CF (age 10e43 years, 7 females) were
non-smokers recruited from the CF outpatient clinic in
Uppsala University Hospital, Sweden. Twelvewere colonized
with opportunistic bacterial strains in their airways,
according to current sputum cultures; i.e. Pseudomonas
(nZ 7), Staphylococcus aureus (nZ 5), Klebsiella and Xan-
thomonas. Ten of the colonized subjects were undertreatment with oral and/or inhaled antibiotics (e.g. tobra-
mycin). All 15 received regular treatment with bronchodi-
lators and expectorants. Five of the CF patientswere treated
with inhaled corticosteroids. A few had mild airway symp-
toms, such as cough, but none had an acute exacerbation
upon testing. Patient data were compared with the results
obtained from 15 non-smoking healthy controls (age 9e44
years, 9 females) e with no previous history of allergy or
airway disease.
The study was approved by the regional ethics committee
and all the subjects were included after written informed
consent from the subjects or their parents (<18 years).
Measurement of FENO
Measurements of FENO were performed according to the
ATS/ERS guidelines2 with chemiluminescence technique
using the Niox (Aerocrine AB, Solna, Sweden). Exhalation
flow rate was set to 0.05 l/s, ensured by the analyser’s
dynamic resistance e if oral pressure was kept between 8
and 20 cm H2O. NO concentration (ppb) was registered as
the mean value from three 10 s exhalations.
Collection of exhaled breath condensate and
analysis of nitrite and nitrate
The EBC was collected in a commercial breath condenser
(EcoScreen, Jaeger, Wu¨rzburg, Germany) during tidal
breathing, while wearing a nose-clip. Total exhalation
volumes were monitored to 60 l by a spirometer (SpirProþ,
Jaeger, Germany) attached to the condenser, providing
about 0.5e1.0 ml of EBC fluid. The Teflon-coated collecting
tube of the condenser was then centrifuged for 1 min at
400 g before aliquoting the condensate fluid to sample
tubes for 20 C storage and later analysis.
Random samples were analysed for salivary amylase
(EnzCheck Amylase Assay Kit, Molecular Probes Inc, Eugene,
OR, USA), to confirm negative direct salivary admixture in
the EBC fluid (detection limit 0.1 IU/l, corresponding to
0.3 ng/l protein). All tested samples were negative in this
highly sensitive assay. To avoid nitrite/nitrate contamina-
tion a plasma polymerisation was deposited on the existing
Teflon-coating of the condenser tubes (in-house method at
Institute for Surface Chemistry, Stockholm, Sweden) and
they were thoroughly cleaned in nitrogen-free disinfectant
(Descogen, Jaeger, Germany) between each sampling.
The samples were analysed for nitrite and nitrate with
a commercial fluorometric assay including DAN (2,3-dia-
minonaphthalene) reagent (Cayman Chemical Nitrate/
Nitrite Fluorometric Assay Kit, Ann Arbor, MI, USA),
measuring nitrite concentrations (detection limit 0.2 mM).
For nitrate levels, a second reading of fluorescence, after
the addition of nitrate reductase, was subtracted with the
initial one. Analysis was performed within two months,
during which period nitrite and nitrate maintain stable
according to tests in our lab.
Saliva collection
Unstimulated saliva from each subject was collected in
a polyethylene tube and centrifuged at 400 g for 2 min. A
Figure 1 The influence of salivary nitrite, and its generation
from bacterial nitrate reductase, on nitrite concentrations in
exhaled breath condensate (EBC) from patients with cystic
fibrosis (nZ 15) and controls (nZ 15). Nitrite was analysed in
(a) EBC and (b) saliva before, and 5 min after, a 30 s mouthwash
with anti-bacterial chlorhexidine. (c) Demonstrates the corre-
lation between salivary and EBC nitrite at baseline. Note loga-
rithmic concentration scales. CFZ cystic fibrosis, m.w.Z after
mouthwash. )p< 0.05, ))p< 0.01, )))p< 0.001.
Exhaled nitrogen oxides in cystic fibrosis 189supernatant of 200 ml was aliquoted and stored in 20 C
for later analysis of nitrite and nitrate, as described
above.
Mouthwash with chlorhexidine
Each of the procedures above was repeated 5 min after
a 30 s mouthwash with an anti-bacterial solution (0.2%
chlorhexidine gluconate with 0.01% menthol).
Statistical analysis
For group comparisons nonparametric ManneWhitney test
was used. For within-group analysis of paired observations,
i.e. before and after chlorhexidine mouthwash, nonpara-
metric Wilcoxon signed rank test was applied. The results
are presented as median values in text and figures (hori-
zontal bars in the scatter-plots). Correlations were ana-
lysed with nonparametric Spearman rank test. All statistics
were conducted with commercial software (Prism4,
GraphPad Software, San Diego, CA, USA).
Results
Nitrite in EBC and saliva
The median level of EBC nitrite was significantly elevated in
the patients with CF as compared to controls (3.6 vs 1.3 mM,
p< 0.05). Mouthwash with chlorhexidine markedly reduced
EBC nitrite, both in the patients with CF (3.6e1.4 mM,
p< 0.01) and in healthy controls (1.3e0.5 mM, p< 0.01). The
difference in median nitrite levels between the two groups
decreased by 60%, from 2.2 to 0.9 mM, but remained statis-
tically significant (1.4 vs 0.5 mM, p< 0.01) due to a lower
degree of scattering. For further details, see Fig. 1a.
Salivary nitrite was, in parallel, significantly higher in
the patients with CF as compared to controls (median 219.6
vs 55.0 mM, p< 0.01). Also here, median levels decreased
considerably in both groups after mouthwash with chlo-
rhexidine (219.6e63.5 mM, p< 0.001 and 55.0e19.8 mM,
p< 0.01), but the statistical significance of the higher
salivary nitrite content in CF remained (63.5 vs 19.8 mM,
p< 0.01). See Fig. 1b.
In addition, there was a strong correlation between
baseline nitrite levels in EBC and saliva (rZ 0.60,
p< 0.001; Fig. 1c), which was still present after mouthwash
(rZ 0.44, p< 0.05; not shown).
Nitrate in EBC and saliva
In contrast to nitrite, therewere no significant differences of
EBC nitrate between the CF group and the controls, either
before (median 7.8 vs 8.2 mM, pZ 0.80) or after chlorhex-
idine (median 8.8 vs 9.3 mM, pZ 0.59), as seen in Fig. 2a.
The median level of salivary nitrate was higher in the CF
group, but the difference was not statistically significant at
baseline due to considerable spread of data (median 189.8
vs 31.0 mM, pZ 0.20). However, after a general increase in
salivary nitrate after mouthwash (CF: 189.8e964.3 mM,
p< 0.01; controls: 31.0e226.8 mM, p< 0.05) the nitratecontent in CF saliva also proved significantly higher (964.3
vs 226.8 mM, p< 0.05). See Fig. 2b.
No significant correlation could be established between
nitrate in EBC and saliva (rZ 0.28, pZ 0.15; Fig. 2c).
Exhaled nitric oxide
There was a statistical trend towards lower levels of FENO
in the patients with CF as compared to controls (median 9.5
Figure 2 Nitrate concentrations in (a) exhaled breath
condensate (EBC) and (b) saliva from cystic fibrosis patients
(nZ 15) and controls (nZ 15) before and after mouthwash
with anti-bacterial chlorhexidine. There was no significant
correlation between nitrate concentrations in saliva and EBC as
demonstrated in (c). Note logarithmic concentration scales.
CFZ cystic fibrosis, m.w.Z after mouthwash, n.s.Z non-
significant. )p< 0.05, ))p< 0.01.
Figure 3 Salivary contribution to exhaled nitric oxide (FENO)
in cystic fibrosis patients (nZ 15) and controls (nZ 15), as
demonstrated by decreased levels after anti-bacterial mouth-
wash e preventing oral nitrite formation. FENO was measured
before, and 5 min after, chlorhexidine application. CFZ cystic
fibrosis, m.w.Z after mouthwash. ())pZ 0.08, )p< 0.05,
)))p< 0.001.
190 W. Zetterquist et al.vs 10.6 ppb, pZ 0.081) at baseline. When chlorhexidine
was applied, FENO levels not only markedly dropped for
both CF patients (median 9.5e5.4 ppb, p< 0.001) and
controls (10.6e8.4 ppb, p< 0.0001), but it also increased
the difference in FENO between the two groups, making the
lower levels in the CF group statistically significant (5.4 vs
8.4 ppb, pZ 0.023). See Fig. 3.
Baseline levels of FENO showed no significant correlation
to EBC nitrite or nitrate (rZ0.29, pZ 0.12 and rZ 0.19,
pZ 0.31, respectively).Discussion
In this study on CF patients we explain the discrepancy of
elevated exhaled NO metabolites with simultaneously low
levels of FENO by demonstrating an influence from saliva
and bacterial activity in the oro-pharyngeal tract.
The median level of EBC nitrite was markedly higher in
the CF group and differed significantly from the controls,
which compares well with previous studies.16,17 However,
chlorhexidine mouthwash, which has a very potent anti-
microbial effect,24 reduced the EBC nitrite levels by more
than 60%, in both the CF and control group, and decreased
interindividual variation. Since there is a substantial
amount of nitrite in the saliva, which is formed through
conversion of salivary nitrate by the bacterial enzyme
nitrate reductase,19 these findings imply that the major
part of EBC nitrite originates in the pharyngo-oral tract.
Nitrate reductase is predominantly found in facultative
anaerobics on the posterior surface of the tongue25 and its
reducing activity can be effectively blocked by chlorhex-
idine mouthwash.26 In fact, the presence of nitrite in the
saliva is completely dependent upon bacterial reduction of
nitrate, which is demonstrated by a total lack of nitrite in
saliva collected directly from the parotid glands27 and in
saliva from germ-free rats.20 The bacterial formation of
nitrite represents a symbiotic relationship which provides
host defence against microbial pathogens in the oral cavity
and the gut through the further non-enzymatic reduction of
nitrite to NO.20 The comparatively higher levels of nitrite in
both EBC and saliva from CF patients indicate that they
have an altered activity of nitrate reducing bacteria,
perhaps even of bacteria in general, in the oral cavity.
The pharyngo-oral origin of EBC nitrite is further sup-
ported by the strong correlation observed between the
concentrations of nitrite in EBC and saliva in this study. Thus,
salivary nitrite was also significantly higher in the CF group
than in the controls. After mouthwash, it decreased by
approximately 70% in both groups, corresponding well with
Exhaled nitrogen oxides in cystic fibrosis 191the parallel reduction of EBC nitrite. Our data of elevated
salivary nitrite in CF are in line with a previous study by
Grasemann et al., even though they reported on the joint
concentration of salivary nitrite and nitrate and interpreted
this as a sign of increased NO activity in the lower airways.28
Since the levels of EBC nitrite remained higher in the CF
group even after the anti-bacterial mouthwash one can
speculate whether there is yet another mechanism
involved. However, there was a marked reduction by 60% of
the difference and such an additional source would then be
of secondary importance in terms of nitrite quantities.
Furthermore, since also salivary nitrite levels remained
higher in the CF patients after chlorhexidine the remaining
difference in EBC nitrite is more likely explained by
a limited ability of the mouthwash to erase all bacterial
activity in the oral cavity and pharynx. This could be due to
an incomplete antimicrobial effect of chlorhexidine and to
the difficulty in rinsing the entire pharyngo-oral tract, as it
elicits an unpleasant swallowing reflex. Nevertheless,
a minor contribution from nitrate reducing bacteria below
the pharynx, which could be more pronounced in the CF
airways, is still possible.
In contrast to nitrite, there was no significant increase of
nitrate in EBC from the CF patients. With the observed
decrease of nitrite after the mouthwash, one could perhaps
expect the nitrate concentrations to elevate. This was true
for the salivary concentrations of nitrate, but not for EBC
nitrate. In addition, there was no correlation between
baseline concentrations of nitrate in saliva and EBC, as in
the case of nitrite. The most probable explanation for this
is that nitrate in EBC mainly originates in the lower airways.
However, a quantitatively smaller salivary contribution of
nitrate to EBC certainly occurs, but it is likely to be over-
shadowed by the bronchially derived nitrate. This is sup-
ported by a study from Marteus et al. on tracheostomised
patients, which showed similar amounts of nitrate in EBC,
when collected both through the tracheostomy and through
oral breathing, whereas EBC nitrite was almost exclusively
found in the orally exhaled air.23
Nevertheless, since the CF group presented an over-all
elevated content of salivary nitrate, but no increase at all
of EBC nitrate, one could assume that their proportion of
bronchial nitrate is lower than in the control group. This
corresponds well with the low levels of exhaled NO in CF
and recent studies which demonstrate that induction of
NO synthesis in the airways generates formation of
nitrate, rather than nitrite.29 Consequently, an increase of
EBC nitrite but not nitrate, as in this study, does hardly
reflect an induced bronchial NO production, but rather
suggests an alternative source of the nitrite e i.e. the
salivary one.
The CF patients presented low levels of exhaled NO,
which is consistent with previous findings.11 However, given
the intense inflammatory activity in the CF airways, this
moderate NO output is puzzling and not yet fully explained.
One contributing factor could be that the inflammatory
process in CF is characterised by a predominantly neutro-
philic activity,10 whereas iNOS expression and exhaled NO
mainly increase by eosinophilic inflammation.30 That argu-
ment is not fully convincing, though, as even viral respira-
tory tract infections in non-CF patients present increased
levels of FENO.31,32 Another often suggested explanation isattributed to the thick and characteristic mucus that lines
the airway epithelium in CF and possibly prevents the
diffusion of NO to the lumen.11 This has been proposed to
cause an accumulation of nitrogen metabolites, as shown in
airway samples from CF patients, and argued to disguise
a genuinely increased NO formation. Apart from elevated
nitrite in EBC16,17 and increased nitrite/nitrate in saliva,28
there are CF studies demonstrating elevated nitrotyrosine
in EBC33 and lung tissue,34 as well as raised content of
nitrotyrosine and nitrate in sputum.35 However, this obvi-
ously conflicts with our data as we cannot show increased
formation of nitrite and nitrate in the lower airways of CF.
The reported increase of nitrotyrosine in CF could possibly
be explained by an elevated presence of superoxide, due to
a more active neutrophilic inflammation, rather than an
increased NO metabolism. Elevated sputum nitrate could,
furthermore, consist of a salivary contribution or be a result
of decreased water content in CF sputum36 and hence
a general increase in the concentration of just about any
substance analysed. Therefore, it is more likely that the
low levels of FENO in CF are caused by a genuinely altered
formation of NO. Findings of a decreased expression of iNOS
in the CF bronchial epithelium,37,38 as well as an impaired
signalling system in vitro of this enzyme,39 constitute
strong support for this. The markedly lower nasal NO levels
reported in CF patients,6,40 along with reduced expressions
of NOS-enzymes in their nasal mucosa,41 indicate the same.
Furthermore, in performed studies on FENO in CF, the
bronchially derived proportion is probably overestimated,
as we could demonstrate an increased contribution to
exhaled NO from the saliva and the non-enzymatic reduc-
tion of nitrite with the chlorhexidine mouthwash. Since NO
is believed to have beneficial properties in the inflamed
airway mucosa, such as bronchodilatation and hoste
defence against microorganisms, the reduced presence of
NO might contribute to the pathology of the CF lung.11
Finally, regarding the chlorhexidine mouthwash, we
vindicate that its effects on nitrite in EBC and saliva, and
consequently on FENO, are explained by diminished
bacterial conversion of nitrate to nitrite in the oral cavity
and pharynx. Chlorhexidine has sustained bacteriostatic
and bactericidal properties24 and it has shown to be
particularly efficient in suppressing the activity of nitrate
reductase.26 The anti-bacterial effect of mouthwash and
dental topical application with chlorhexidine is well docu-
mented and bacterial growth has been shown to be mark-
edly reduced in saliva, sputum and tissue cultures taken
after its administration.42e44 It could perhaps be argued
that the reduced content of nitrite in EBC and saliva after
chlorhexidine is more of a rinsing effect, but then it would
not cause an increase in salivary nitrate, as we observed.
Furthermore, previous studies have not shown any effect on
either nitrite in EBC and saliva23 or FENO21 from rinsing the
mouth with plain water.
Therefore, we conclude that elevated levels of EBC
nitrite in CF patients originate in the saliva, through
increased activity of pharyngo-oral bacteria, and are not
the result of an induced NO formation in the bronchi and
lower airways. Together with the moderate levels of EBC
nitrate and the results of FENO this supports the idea of
a genuinely restrained NO synthesis in the respiratory
epithelium of CF, as there are no further traces of increased
192 W. Zetterquist et al.NO metabolism in spite of the pronounced chronic infec-
tion. Thus, the paradox of low exhaled NO from the
inflamed airways of CF is not primarily explained by its
trapping behind a mucus barrier but rather by an impaired
function or expression of the NO producing enzymes.
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